Our project aimed at developing oncological active ingredients and preparations has concluded successfully

Over the past four years, our company has made significant progress in the field of oncological active ingredient and preparation development, thanks to the support received through the project titled ´Development of innovative, high added value oncological drug preparations for personalized therapies.´ During the period from 2021 to 2024, we worked on the development of 14 active ingredients and 5 preparations in collaboration with our consortium partner, HUN-REN TTK.

Innovation

Our project aimed at developing oncological active ingredients and preparations has concluded successfully

Mon, Feb 24, 2025 9:16 AM

Author:

Mon, Feb 24, 2025 9:16 AM

Author:

During the project period, 12 laboratory syntheses were developed for the active ingredients, and for 5 active ingredients, scale-up to pilot plant size was also achieved. For professional or economic reasons, we terminated 3 developments after the laboratory phase and another 3 after the pilot plant scale-up. The active ingredients developed in the project were incorporated into 4 preparations during the formulation development, and further incorporation of active ingredients is expected in the future.

One preparation has already been introduced to the market and is generating revenue for Egis. The development of certain preparations was halted due to polymorphism and stability issues, while our other developments are progressing without interruptions according to the planned schedule. Due to patent reasons, the introduction of additional products from the portfolio is expected after 2030. Timely developments allow for the possibility of these generic drugs being marketed in countries where Egis does not have a commercial organization, through partnerships. During the project, numerous professional achievements were made, enhancing our oncological drug development capabilities and practical knowledge. Beyond the revenue generated by the products realized with the support, the project indirectly contributes to the development of further drugs and the future sustainable success of the company's oncological portfolio.

Our project aimed at developing oncological active ingredients and preparations has concluded successfully

Our project aimed at developing oncological active ingredients and preparations has concluded successfully

Innovation

Development of Innovative, High Value-Added Oncological Drug Products for Personalized Therapies

Innovation

Egis' medicines won the Innovation Grand Prize

Innovation

Egis expands its portfolio with active pharmaceutical ingredient contract development and contract manufacturing

Cookie Settings

Cookies necessary for basic functioning

Functional cookies

Cookies for statistical purposes

Cookie management policy